

# 2017 Assessment of Evaluation and Treatment Planning Prostate Cancer

**STUDY PURPOSE: To assess if Stage I and II Prostate cases diagnosed and treated at St Joseph Hospital Eureka have diagnostic workup and treatment based on NCCN Guidelines.**

CoC Cancer Program Requirement: Standard 4.6; Assessment and Evaluation of Treatment Planning: Each year, a physician member of the cancer committee performs a study to assess whether patients are evaluated and treated according to evidence-based national treatment guidelines. The study must determine that the diagnostic evaluation is adequate and the treatment plan is concordant with a recognized guideline.

**Physician Member of Cancer Committee to perform study:** M. Ellen Mahoney, MD

**Background:** The study conducted by Cancer Committee this year analyzed the diagnostic and treatment patterns of Prostate patients compared to the NCCN (National Comprehensive Cancer Network) Version 3.2016.

**Site Specific Sample:** Prostate Cancer  
**Accession Year:** 2017, Class of Case 00-22

**Focus on AJCC Stage:** Stage I, IIA and IIB

**2017 Total Cases:** Stage I = 9  
 Stage IIA = 14  
 Stage IIB = 20

## Diagnostic Evaluation and Primary Treatment based on NCCN Guidelines:

- Pathology Report should contain; histology, Gleason primary and secondary grade.
- History and Physical with attention to; PSA pre-operative value, documentation of DRE (Digital Rectal Exam)
- Bone Scan for PSA over 20 for T1 lesion, PSA over 10 for T2 lesion, Gleason score greater than 8.

## 2017 Prostate Cancer; Study Assessment Summary:

A review of the 2017 Prostate cases notes (9) Stage I, (34) Stage II, (5) Stage 3, and (9) Stage 4 cases. 100% histologically confirmed diagnoses. Ethnicity; 93% White, 3.5% African American and 3.5% Hispanic. Ages ranged from 56 to 96 with the median age at diagnosis being 68.4 years of age.

## Diagnostic Evaluation:

Pathology data elements per NCCN guidelines

<u>Histology</u>	<u>Gleason Primary</u>	<u>Gleason Secondary</u>
100%	100%	100%

History and Physical elements per NCCN guidelines

<u>Pre-Operative PSA</u>	<u>Documented DRE</u>
100%	100%

Bone Scan for PSA over 20 for T1 lesion or PSA over 10 for T2 lesion, Gleason score greater than 8.  
 100% N = 9


**Evaluation:**

St Joseph Hospital Eureka consistently met the NCCN guidelines for diagnostic workup of prostate cases.


**Recommendations:**

Guidelines are met consistently over the 2017 study year.


**St Joseph Hospital Eureka 2017 Prostate Cases with National Cancer Database (NCDB) comparison**



Age	SJE	NCDB
50-59	9%	21.96%
60-69	47%	44.26%
70-79	33%	24.66%
80-89	9%	5.89%
90+	2%	0.75%



Stage	SJE	NCDB
I	16%	19.38%
II	60%	53.84%
III	9%	13.34%
IV	15%	4.85%



Race	SJE	NCDB
White	93%	75.42%
African American	2%	15.5%
Hispanic	2%	4.85%

## St Joseph Hospital Eureka 2017 Prostate Cases with National Cancer Database (NCDB) comparison

Treatment		SJE	NCDB
	Biopsy	100%	67%
	Surgery	28%	45.90%
	Radiation	44%	13.30%
	Radiation/Surgery	11%	1.63%

### Summary:

St Joseph Hospital Eureka data reflects for 2017 a slightly older population of newly diagnosed cases in 2017 over the national trend, however this coincides completely with the local older population demographics. Of the cases diagnosed 15% were found to be at the distant stage, this is 10% higher than the national trend. Both of these local trends are reflected in our higher than average radiation treatment rates. We anticipate continued research regarding this data in our 2019 quality studies.

We recommend ACS guidelines to encourage shared decision making regarding Prostate Specific Antigen Test (PSA) for men 50 and over to identify prostate cancer at an earlier and treatable stage of disease.